Literature DB >> 7609062

Human herpesvirus 6A ts suppresses both transformation by H-ras and transcription by the H-ras and human immunodeficiency virus type 1 promoters.

J C Araujo1, J Doniger, F Kashanchi, P L Hermonat, J Thompson, L J Rosenthal.   

Abstract

Human herpesvirus 6 strain U1102 (HHV-6A) was shown to contain a 1,473-bp functional transformation suppressor gene (ts). ts exhibited 24% identity and 51% similarity to adeno-associated virus type 2 Rep68/78. Like adeno-associated virus type 2 Rep68/78, HHV-6A ts suppressed H-ras transformation of NIH 3T3 cells. Suppression of H-ras transformation was eliminated by translation termination linker mutation at amino acid 25, 125, or 245. These data indicated the importance of the C-terminal portion of the ts protein. H-ras transformation was suppressed by ts only when H-ras was expressed by its endogenous H-ras promoter and not when it was expressed by the heterologous murine osteosarcoma virus long terminal repeat (LTR). Furthermore, ts suppressed chloramphenicol acetyltransferase (CAT) activity when the CAT gene was expressed from the H-ras promoter but not the murine osteosarcoma virus LTR promoter. Taken together, the data showed that ts suppressed H-ras transformation at the level of the H-ras promoter. To further identify the interaction of ts with transcriptional regulatory elements, the human immunodeficiency virus type 1 (HIV-1) LTR was used. This promoter was selected because it has well-defined transcriptional regulatory elements for both basal and activated transcription, because its activity is inhibited by the Rep68/78 gene, and because both HHV-6 and HIV-1 naturally infect CD4+ T cells in vivo and have been shown to infect the same cell in vitro. ts suppressed expression from both wild-type and upstream mutant HIV-1 LTR-CAT constructs. However, downstream HIV-1 TAR mutations reversed ts suppression, indicating that TAR is one of the critical elements involved. The data presented demonstrated that HHV-6A ts functionally suppressed H-ras transformation and HIV-1 LTR expression and thus that it may be useful in future gene therapy.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7609062      PMCID: PMC189308          DOI: 10.1128/JVI.69.8.4933-4940.1995

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  58 in total

1.  Transforming genes of human bladder and lung carcinoma cell lines are homologous to the ras genes of Harvey and Kirsten sarcoma viruses.

Authors:  C J Der; T G Krontiris; G M Cooper
Journal:  Proc Natl Acad Sci U S A       Date:  1982-06       Impact factor: 11.205

2.  Binding of the Sp1 transcription factor by the human Harvey ras1 proto-oncogene promoter.

Authors:  S Ishii; J T Kadonaga; R Tjian; J N Brady; G T Merlino; I Pastan
Journal:  Science       Date:  1986-06-13       Impact factor: 47.728

3.  Positive and negative autoregulation of the adeno-associated virus type 2 genome.

Authors:  M A Labow; P L Hermonat; K I Berns
Journal:  J Virol       Date:  1986-10       Impact factor: 5.103

4.  Transforming ras genes from human melanoma: a manifestation of tumour heterogeneity?

Authors:  A P Albino; R Le Strange; A I Oliff; M E Furth; L J Old
Journal:  Nature       Date:  1984 Mar 1-7       Impact factor: 49.962

5.  Ha-ras oncogenes are activated by somatic alterations in human urinary tract tumours.

Authors:  J Fujita; O Yoshida; Y Yuasa; J S Rhim; M Hatanaka; S A Aaronson
Journal:  Nature       Date:  1984 May 31-Jun 6       Impact factor: 49.962

6.  Molecular cloning and the total nucleotide sequence of the human c-Ha-ras-1 gene activated in a melanoma from a Japanese patient.

Authors:  T Sekiya; M Fushimi; H Hori; S Hirohashi; S Nishimura; T Sugimura
Journal:  Proc Natl Acad Sci U S A       Date:  1984-08       Impact factor: 11.205

7.  Genetics of adeno-associated virus: isolation and preliminary characterization of adeno-associated virus type 2 mutants.

Authors:  P L Hermonat; M A Labow; R Wright; K I Berns; N Muzyczka
Journal:  J Virol       Date:  1984-08       Impact factor: 5.103

8.  A position 12-activated H-ras oncogene in all HS578T mammary carcinosarcoma cells but not normal mammary cells of the same patient.

Authors:  M H Kraus; Y Yuasa; S A Aaronson
Journal:  Proc Natl Acad Sci U S A       Date:  1984-09       Impact factor: 11.205

9.  Detection of human B-lymphotropic virus (human herpesvirus 6) sequences in B cell lymphoma tissues of three patients.

Authors:  S F Josephs; A Buchbinder; H Z Streicher; D V Ablashi; S Z Salahuddin; H G Guo; F Wong-Staal; J Cossman; M Raffeld; J Sundeen
Journal:  Leukemia       Date:  1988-03       Impact factor: 11.528

10.  Promoter region of the human Harvey ras proto-oncogene: similarity to the EGF receptor proto-oncogene promoter.

Authors:  S Ishii; G T Merlino; I Pastan
Journal:  Science       Date:  1985-12-20       Impact factor: 47.728

View more
  17 in total

Review 1.  Human herpesvirus 6.

Authors:  D K Braun; G Dominguez; P E Pellett
Journal:  Clin Microbiol Rev       Date:  1997-07       Impact factor: 26.132

2.  Temporal mapping of transcripts in herpesvirus 6 variants.

Authors:  P Mirandola; P Menegazzi; S Merighi; T Ravaioli; E Cassai; D Di Luca
Journal:  J Virol       Date:  1998-05       Impact factor: 5.103

3.  Detection of antibodies directed against human herpesvirus 6 U94/REP in sera of patients affected by multiple sclerosis.

Authors:  Elisabetta Caselli; Michela Boni; Arianna Bracci; Antonella Rotola; Claudio Cermelli; Massimiliano Castellazzi; Dario Di Luca; Enzo Cassai
Journal:  J Clin Microbiol       Date:  2002-11       Impact factor: 5.948

Review 4.  Update on human herpesvirus 6 biology, clinical features, and therapy.

Authors:  Leen De Bolle; Lieve Naesens; Erik De Clercq
Journal:  Clin Microbiol Rev       Date:  2005-01       Impact factor: 26.132

Review 5.  The molecular biology of human herpesvirus-6 latency and telomere integration.

Authors:  Jesse H Arbuckle; Peter G Medveczky
Journal:  Microbes Infect       Date:  2011-03-31       Impact factor: 2.700

6.  Expression of human herpesvirus 6B rep within infected cells and binding of its gene product to the TATA-binding protein in vitro and in vivo.

Authors:  Y Mori; P Dhepakson; T Shimamoto; K Ueda; Y Gomi; H Tani; Y Matsuura; K Yamanishi
Journal:  J Virol       Date:  2000-07       Impact factor: 5.103

Review 7.  Horizontal gene transfers with or without cell fusions in all categories of the living matter.

Authors:  Joseph G Sinkovics
Journal:  Adv Exp Med Biol       Date:  2011       Impact factor: 2.622

8.  U94 of human herpesvirus 6 is expressed in latently infected peripheral blood mononuclear cells and blocks viral gene expression in transformed lymphocytes in culture.

Authors:  A Rotola; T Ravaioli; A Gonelli; S Dewhurst; E Cassai; D Di Luca
Journal:  Proc Natl Acad Sci U S A       Date:  1998-11-10       Impact factor: 11.205

9.  U94 of human herpesvirus 6 inhibits in vitro angiogenesis and lymphangiogenesis.

Authors:  Arnaldo Caruso; Elisabetta Caselli; Simona Fiorentini; Antonella Rotola; Alberto Prandini; Emirena Garrafa; Elisa Saba; Giulio Alessandri; Enzo Cassai; Dario Di Luca
Journal:  Proc Natl Acad Sci U S A       Date:  2009-11-16       Impact factor: 11.205

Review 10.  Viral Proteins as Emerging Cancer Therapeutics.

Authors:  Ekta Manocha; Arnaldo Caruso; Francesca Caccuri
Journal:  Cancers (Basel)       Date:  2021-05-03       Impact factor: 6.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.